Jupiter Neurosciences has signed a $100 million term sheet to acquire exclusive U.S. rights to ALA-002, a next-generation MDMA-based therapeutic developed by PharmAla Biotech. ALA-002 is designed to improve safety and reduce abuse risk compared to traditional MDMA while enhancing therapeutic effects for conditions like PTSD and anxiety. This deal positions Jupiter at the forefront of the emerging psychedelic medicine market, which is expected to grow into a multi-billion-dollar industry in the U.S. The acquisition aligns with recent U.S. regulatory support for psychedelic therapies, including an executive order accelerating access and development. Jupiter plans to finalize the agreement within 90 days and aims to advance ALA-002 through clinical and regulatory pathways to capitalize on expanding market opportunities.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Brazil Potash Corp. disclosed a procedural filing by the Brazilian Federal Public Defender’s Office seeking to suspend activities at its Autazes potash project. The filing challenges prior favorable court decisions but does not introduce new facts or...
DT Midstream, Inc. will announce its financial results for the second quarter of 2026 before the market opens on July 30, 2026. The company has scheduled a conference call at 9:00 a.m. ET on the same day to discuss the results. Investors and the publ...
UK GDP grew 0.8% over three months, beating expectations and showing resilience despite geopolitical risks. The FTSE 100 opened lower amid mixed company results, with major takeovers announced for Rotork (£4.1bn by ABB), Gooch & Housego (£345.6m by A...
Bitcoin briefly reached a three-week high near $65,600 before retreating to around $64,000, influenced by lower-than-expected US inflation data and geopolitical tensions. Ethereum also reversed from a six-week peak near $1,950, slipping below $1,900....
